QURE Dec 2023 10.000 call
| Previous close | 14.17 |
| Open | N/A |
| Bid | 12.60 |
| Ask | 16.90 |
| Strike | 10.00 |
| Expiry date | 2023-12-15 |
| Day's range | 14.17 - 14.17 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
- GlobeNewswire
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
~ License of APB-102 further strengthens uniQure’s pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~ ~ APB-102 and uniQure’s c9orf72-ALS program have the potential to address most inherited forms of ALS ~~ uniQure plans to initiate a Phase I/II trial of APB-102 in the second half of 2023 ~ LEXINGTON, Mass. and AMSTERDAM and CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
- Motley Fool
3 Growth Stocks That Could Rocket Higher in 2023
If you're looking for stocks that can make dramatic gains quickly, it's hard to do any better than the biotechnology industry. Hardly a week goes by without at least one biotech stock shooting higher or tumbling lower in response to exciting news about experimental treatments. In 2023, all three of these drugmakers will report study results that are awfully important to their futures.
- GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass. and AMSTERDAM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to employees as a material inducement to commencing their employment. The equity grants were approved by the Company’s board of directors on December 7, 2022, October 31, 2022, and September 27, 2022 (the “Grant Dates”) each in accordance with
